NCT04656600 - Study to Evaluate Efficacy and Safety of Imiglucerase Treatment in Chinese Patients With Gaucher Disease Type Ⅲ | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 2, 2021

Primary Completion Date

October 12, 2023

Study Completion Date

October 12, 2023

Conditions

Gaucher's Disease

Interventions

DRUG

Cerezyme® / Imiglucerase

Pharmaceutical form: lyophilisate for solution for infusion Route of administration: intravenous

Trial Locations (5)

Investigational Site Number : 107, Beijing

Investigational Site Number : 101, Beijing

Investigational Site Number : 102, Guangzhou

Investigational Site Number : 105, Guangzhou

Investigational Site Number : 104, Chengdu